On 25 July 2025, Opyl Limited (ASX: OPL) officially rebranded to Pathkey.AI (ASX: PKY) – a move signalling a sharpened focus on applying artificial intelligence to the most critical challenges in clinical trials and drug development. Rather than being “just another med-tech rebrand,” Pathkey.AI represents a company building a sophisticated decision-support ecosystem designed to help therapies get to patients faster, de-risk trials for sponsors, and improve capital efficiency